AMRN
Price
$13.60
Change
-$0.34 (-2.44%)
Updated
Jul 20 closing price
Capitalization
285.18M
Intraday BUY SELL Signals
CNTB
Price
$2.20
Change
-$0.18 (-7.56%)
Updated
Jul 20 closing price
Capitalization
138.52M
56 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMRN vs CNTB

AMRN vs CNTB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AMRN vs. CNTB commentary
Jul 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a StrongBuy and CNTB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2026
Stock price -- (AMRN: $13.60 vs. CNTB: $2.20)
Brand notoriety: AMRN: Notable vs. CNTB: Not notable
AMRN represents the Pharmaceuticals: Major, while CNTB is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMRN: 46% vs. CNTB: 86%
Market capitalization -- AMRN: $285.18M vs. CNTB: $138.52M
AMRN [@Pharmaceuticals: Major] is valued at $285.18M. CNTB’s [@Biotechnology] market capitalization is $138.52M. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $1.02T to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $121.95B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $191.39B. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRN’s FA Score shows that 0 FA rating(s) are green whileCNTB’s FA Score has 0 green FA rating(s).

  • AMRN’s FA Score: 0 green, 5 red.
  • CNTB’s FA Score: 0 green, 5 red.
According to our system of comparison, CNTB is a better buy in the long-term than AMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRN’s TA Score shows that 4 TA indicator(s) are bullish while CNTB’s TA Score has 3 bullish TA indicator(s).

  • AMRN’s TA Score: 4 bullish, 6 bearish.
  • CNTB’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, AMRN is a better buy in the short-term than CNTB.

Price Growth

AMRN (@Pharmaceuticals: Major) experienced а -7.48% price change this week, while CNTB (@Biotechnology) price change was -2.65% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.84%. For the same industry, the average monthly price growth was +2.24%, and the average quarterly price growth was +5.47%.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.90%. For the same industry, the average monthly price growth was +0.93%, and the average quarterly price growth was +1849.76%.

Reported Earning Dates

CNTB is expected to report earnings on Sep 15, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (-1.84% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Biotechnology (-3.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMRN($285M) has a higher market cap than CNTB($139M). AMRN YTD gains are higher at: -2.544 vs. CNTB (-21.986). AMRN has higher annual earnings (EBITDA): -24.36M vs. CNTB (-65.54M). AMRN has more cash in the bank: 308M vs. CNTB (46M). CNTB has less debt than AMRN: CNTB (693K) vs AMRN (5.59M). AMRN has higher revenues than CNTB: AMRN (217M) vs CNTB (233K).
AMRNCNTBAMRN / CNTB
Capitalization285M139M205%
EBITDA-24.36M-65.54M37%
Gain YTD-2.544-21.98612%
P/E RatioN/AN/A-
Revenue217M233K93,133%
Total Cash308M46M670%
Total Debt5.59M693K806%
FUNDAMENTALS RATINGS
AMRN: Fundamental Ratings
AMRN
OUTLOOK RATING
1..100
76
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
72
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AMRNCNTB
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 28 days ago
74%
Bullish Trend 7 days ago
89%
Declines
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 9 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AMRN
Daily Signal:
Gain/Loss:
CNTB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OSCCX23.07N/A
N/A
Invesco Main Street Small Cap C
PRITX22.71N/A
N/A
T. Rowe Price International Stock
IGMAX7.07N/A
N/A
Voya Global Insights R
PGJAX19.26N/A
N/A
PGIM Jennison Global Infrastructure A
BARDX9.16N/A
N/A
iShares Developed Real Estate Idx Inv A

AMRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with CNTB. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then CNTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRN
1D Price
Change %
AMRN100%
-2.44%
CNTB - AMRN
55%
Loosely correlated
-7.56%
HRTX - AMRN
44%
Loosely correlated
+2.06%
MGNX - AMRN
44%
Loosely correlated
-3.79%
ALXO - AMRN
43%
Loosely correlated
-8.57%
ARWR - AMRN
40%
Loosely correlated
-3.57%
More